Zai Lab advances zoci to global Phase 3
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Zai Lab reported positive Phase 1b results for zocilurtatug pelitecan combined with atezolizumab in extensive stage small cell lung cancer, citing high objective response rates and a tolerable safety profile. The company plans to advance zoci into a global Phase 3 program, shaping its oncology portfolio and R&D spending priorities. A US$250 million private placement will fund expanded trials.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.